NYSE · LLY
Eli Lilly and Company
$1,431.52+$57.82 (+4.21%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
Loading market information…
OTC · ODTC · USD
Stock price, earnings
Quote as of Jan 14, 2025, 08:39 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Odonate Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.85% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Odonate Therapeutics, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$14,400.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Odonate Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug. This agent is currently undergoing a Phase III clinical study for its application in patients suffering from metastatic breast cancer.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:29 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q3 2020 | Oct 28, 2020 | -$0.93+2.11% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,431.52+$57.82 (+4.21%)
Eli Lilly and Company’s quoted price is above the reported 52-week high. The range and quote may have different update times.
$276.31+$1.11 (+0.4%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.0% below the high.
$295.87+$5.08 (+1.75%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.95% below the high.
$149.31+$2.98 (+2.04%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.89% below the high.
$408.05-$2.86 (-0.7%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 11.62% below the high.
HK$38.10+HK$2.12 (+5.89%)
JD Health International Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.86% below the high.
¥5,052+¥78 (+1.57%)
Eisai Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 3.64% below the high.
$1.98-$0.09 (-4.13%)
TuHURA Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.42% below the high.
